Resistance to extended-spectrum cephalosporins (ESCs) or fluoroquinolones in *Salmonella enterica* has become a global concern ([@R1]). ESC resistance in *Salmonella* strains is usually due to the production of plasmid-mediated extended-spectrum β-lactamases (ESBLs) or AmpC β-lactamases, and among these β-lactamases, the CMY-2 AmpC enzyme has been reported most often ([@R1]--[@R3]). Resistance to fluoroquinolones in *Salmonella* strains is usually due to the accumulation of mutations in the quinolone resistance--determining regions (QRDRs) of DNA gyrase genes ([@R1],[@R4],[@R5]). Resistance to both ESCs and fluoroquinolones remains extremely rare in salmonellae.

In Taiwan, increasing resistance to fluoroquinolones and the emergence of CMY-2--producing ESC-resistant strains in salmonellae have been noted ([@R3]--[@R6]). The emergence of *Salmonella* strains resistant to both ceftriaxone and ciprofloxacin was reported more recently in Taiwan and may pose a serious therapeutic problem ([@R7],[@R8]). We conducted the present study to investigate the prevalence and characteristics of *Salmonella* strains resistant to ciprofloxacin and ESCs in Taiwan.

The Study
=========

From January to May 2004, a total of 600 *Salmonella* isolates from 585 patients were obtained from 5 medical centers and 14 district hospitals throughout Taiwan; these isolates were serotyped with commercial antisera (Difco, Detroit, MI, USA). The 4 most common serotypes of *Salmonella enterica* (Enteritidis, Typhimurium, Stanley, and Choleraesuis) accounted for 66.8% of all isolates. Two isolates were untypeable, and the remainder were typed into 42 serotypes (data not shown), which were each represented by 1 to 23 isolates.

MICs of antimicrobial agents were determined by the agar dilution method ([@R9]). Resistance to ciprofloxacin (MIC ≥4 μg/mL) was seen in 50 (8.3%) isolates ([Table 1](#T1){ref-type="table"}); 20 (3.3%) were resistant (MICs ranging from 8 to \>64 μg/mL) to ceftazidime, ceftriaxone, cefotaxime, or aztreonam ([Table 2](#T2){ref-type="table"}); 6 isolates showed decreased susceptibilities to 1 or 2 of the 4 ESCs (MICs 0.5--2 μg/mL); 10 (1.7%) isolates were resistant to both ciprofloxacin and ESCs. *S*. Choleraesuis had high rates of resistance to ciprofloxacin (84.4%), ESCs (17.8%), and both (17.8%). None of the 26 *Salmonella* isolates with resistance or decreased susceptibility to ESCs produced ESBL, according to the double-disk synergy method ([@R10]). Among the 20 ESC-resistant isolates, 10 isolates were ciprofloxacin-resistant, 4 isolates showed decreased susceptibility to ciprofloxacin (MIC 0.25--1 μg/mL) and resistance to nalidixic acid, and 6 isolates were susceptible to ciprofloxacin and nalidixic acid ([Table 2](#T2){ref-type="table"}). All 20 ESC-resistant isolates were susceptible to cefepime (MIC \<0.03 μg/mL) and imipenem (MIC \<1 μg/mL), and 17 isolates were resistant to \>1 non--β-lactam agent.

###### Resistance to ciprofloxacin, extended-spectrum cephalosporins, and both in *Salmonella enterica* serotypes, by region and pulsotype, Taiwan, January--May 2004

  Resistance and region\*            No. of resistant *S*. *enterica* isolates/no. of total isolates (%)                                                                         
  ---------------------------------- --------------------------------------------------------------------- ----------- ------------ -------------- -------------- -------------- ------------------------------------
  Ciprofloxacin resistance           1/161 (0.6)                                                           0/142 (0)   0/53 (0)     38/45 (84.4)   11/199 (5.5)   50/600 (8.3)   
  Northern                           0/96 (0)                                                              0/38 (0)    0/14 (0)     13/16 (81.3)   6/88 (6.8)     19/252 (7.5)   A (11), D (1), E (1)
  Central                            1/32 (3.1)                                                            0/34 (0)    0/14 (0)     6/8 (75.0)     4/37 (10.8)    11/125 (8.8)   A (5), C (1)
  Southern                           0/25 (0)                                                              0/60 (0)    0/24 (0)     18/20 (90.0)   1/65 (1.5)     19/194 (9.8)   A (14), B (1), C (1), F (1), G (1)
  Eastern                            0/8 (0)                                                               0/10 (0)    0/1 (0)      1/1 (100)      0/9 (0)        1/29 (3.4)     A (1)
  ESC resistance                     0/161 (0)                                                             0/142 (0)   3/53 (5.7)   8/45 (17.8)    9/199 (4.5)    20/600 (3.3)   
  Northern                           0/96 (0)                                                              0/38 (0)    1/14 (7.1)   1/16 (6.3)     7/88 (8.0)     9/252 (3.6)    
  Central                            0/32 (0)                                                              0/34 (0)    1/14 (7.1)   0/8 (0)        1/37 (2.7)     2/125 (0.8)    
  Southern                           0/25 (0)                                                              0/60 (0)    1/24 (4.2)   7/20 (35.0)    1/65 (1.5)     9/194 (4.6)    
  Eastern                            0/8 (0)                                                               0/10 (0)    0/1 (0)      0/1 (0)        0/9 (0)        0/29 (0)       
  Ciprofloxacin and ESC resistance   0/161 (0)                                                             0/142 (0)   0/53 (0)     8/45 (17.8)    2/199 (1.0)    10/600 (1.7)   
  Northern                           0/96 (0)                                                              0/38 (0)    0/14 (0)     1/16 (6.3)     1/88 (1.1)     2/252 (0.8)    E (1)
  Central                            0/32 (0)                                                              0/34 (0)    0/14 (0)     0/8 (0)        1/37 (2.7)     1/125 (0.8)    
  Southern                           0/25 (0)                                                              0/60 (0)    0/24 (0)     7/20 (35.0)    0/65 (0)       7/194 (3.6)    A (4), C (1), F (1), G (1)
  Eastern                            0/8 (0)                                                               0/10 (0)    0/1 (0)      0/1 (0)        0/9 (0)        0/29 (0)       

###### Characteristics of 20 *Salmonella* isolates resistant to extended-spectrum cephalosporins

  Serotype       Specimen type   pI (s)     Resistance pattern\*              *gyrA* at position†                           
  -------------- --------------- ---------- --------------------------------- --------------------- ----------- ----------- ---------------------------------------------
  Albany         Urine           9.0        Am ESC Fx Cm Na Sxt Tc†           --                    AAC (Asn)   --          SA04.028 (C)
  Cairo          Stool           9.0, 5.4   Am ESC Fx Cm Na Gm Km Sxt Tc†     TTC (Phe)             --          --          NC04.001 (H1), NC04.002 (H1), NC04.003 (H1)
                 Urine           9.0        Am ESC Fx Cm Cp Na Sxt Tc         TTC (Phe)             GGC (Gly)   AAC (Arg)   NC04.004 (H2)
  Chester        Stool           9.0        Am ESC Fx                         --                    --          --          NG04.016 (G)
  Choleraesuis   Wound           9.0, 5.4   Am ESC Fx Cm Cp Na Gm Km Sxt Tc   TTC (Phe)             AAC (Asn)   ATC (Ile)   NL04.050 (B)
                 Blood           9.0, 5.4   Am ESC Fx Cm Cp Na Gm Tc          TTC (Phe)             AAC (Asn)   ATC (Ile)   SB04.003 (A)
                 Blood           9.0, 5.4   Am ESC Fx Cm Cp Na Gm Km Sxt Tc   TTC (Phe)             AAC (Asn)   ATC (Ile)   SE04.005 (F), SG04.060
                 Blood           9.0, 5.4   Am ESC Fx Cm Cp Na Gm Km Sxt      TTC (Phe)             AAC (Asn)   ATC (Ile)   SG04.039 (E1), SG04.086
                 Joint fluid     9.0, 5.4   Am ESC Fx Cm Cp Na Gm Km Sxt Tc   TTC (Phe)             AAC (Asn)   ATC (Ile)   SG04.042 (E2), SG04.047 (E4)
  Kaduna         Tissue          9.0, 5.4   Am ESC Fx Cm Cp Na Sxt Tc         TTC (Phe)             AAC (Asn)   ATC (Ile)   CE04.015 (I)
  Saintpaul      Stool           9.0        Am ESC Fx Gm                      --                    --          --          NG04.011 (G), NG04.018 (G)
  Stanley        Stool           9.0, 5.4   Am ESC Fx Cm Sxt Tc               --                    --          --          CG04.039 (D)
                 Stool           9.0        Am ESC Fx Cm Sxt Tc               --                    --          --          NB04.022 (A), SE04.006 (E3)

\*Am, ampicillin; ESC, extended-spectrum cephalosporins; Fx, cefoxitin; Cm, chloramphenicol, Cp, ciprofloxacin; Na, nalidixic acid; Gm, gentamicin; Km, kanamycin; Sxt, trimethoprim-sulfamethoxazole; Tc, tetracycline. †The *S*. Albany isolate and the 3 *S*. Cairo isolates showed decreased susceptibilities to ciprofloxacin (MIC 0.25--1 μg/mL). ‡Nucleotide and amino acid changes at the QRDRs of *gyrA* and *parC*. --, no alterations in the genes. §For each isolate, the first letter indicates region (C, central region; N, northern region; S, southern region), and the second letter represents hospital. Isolates NC04.001, NC04.002, and NC04.003 were from the same patients; all other isolates were from different patients.

All 20 ESC-resistant isolates expressed a β-lactamase of pI 9.0 by isoelectric focusing ([@R3],[@R11]); 11 of these isolates expressed an additional pI 5.4 β-lactamase ([Table 2](#T2){ref-type="table"}). *bla*~CMY-2~ was detected in all ESC-resistant isolates. *bla*~TEM-1~ was detected in the 11 isolates with the pI 5.4 β-lactamase by polymerase chain reaction (PCR) and sequence analyses with the primers for the entire *bla*~TEM~-related and *bla*~CMY-2~-related structural genes ([@R2],[@R3]).

The QRDR sequences of *gyrA*, *gyrB*, *parC*, and *parE* of the 20 ESC-resistant *Salmonella* isolates were determined by PCR and sequence analyses ([@R5]). All 10 ciprofloxacin-resistant isolates showed 2 mutations at the Ser-83 and Asp-87 codons in *gyrA* and a single mutation at the Ser-80 codon in *parC* ([Table 2](#T2){ref-type="table"}). Four isolates with decreased susceptibility to ciprofloxacin had a single mutation at either the Ser-83 or the Asp-87 codon in *gyrA*. All 20 ESC-resistant isolates showed no mutations in the QRDRs of *gyrB* and *parE*.

ESC resistance was transferred from 18 of the 20 ESC-resistant *Salmonella* isolates to *Escherichia coli* C600 in the liquid mating-out assay ([@R3],[@R12]). All transconjugants showed decreased susceptibilities to the 4 ESCs tested (MICs 16--64 μg/mL) and cefoxitin (MIC 64--128 μg/mL) and were susceptible to all non--β-lactam agents tested. A pI 9.0 vz β-lactamase and *bla*~CMY-2~ were detected by isoelectric focusing and PCR assays, respectively, in all transconjugants. Restricted by the endonuclease *Eco*RI, the 18 transferred plasmids produced 9 major restriction patterns ([Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Patterns E and I were further divided into 4 and 2 subtypes, respectively. *bla*~CMY-2~ on the transferred plasmids was demonstrated by Southern hybridization with the *bla*~CMY-2~ probe.

![*Eco*RI restriction patterns of transferred CMY-2--encoding plasmids of 18 *Salmonella* isolates. The result of the hybridization assay with the *bla*~CMY-2~ probe labeled with digoxigenin (Roche Molecular Biochemicals, Mannheim, Germany) is shown below the gel, and arrowheads indicate the locations of the restriction fragments that were hybridized. Lanes 2--21, plasmids from transconjugants of *Salmonella* isolates NB04.022, SB04.003, NL04.050, SA04.028, CG04.039, SG04.039, SG04.042, SE04.006, SG04.047, SE04.005, NG04.011, NG04.016, NG04.018, NC04.001, NC04.002, NC04.003, NC04.004, and CE04.015; lanes 1 and 22, molecular marker II (Roche Molecular Biochemicals); lanes 12 and 13, a 1-kb molecular marker (Promega Co., Madison, WI, USA).](04-1153-F1){#F1}

The 38 ciprofloxacin-resistant *S*. Choleraesuis isolates were genotyped by pulsed-field gel electrophoresis on a CHEF Mapper apparatus (Bio-Rad Laboratories, Hercules, CA, USA) according to the PulseNet protocol ([@R13]). Banding patterns generated by *Xba*I restriction were compared with BioNumerics software (Applied Maths, Kortrijk, Belgium). The 38 isolates showed a close relationship (Dice correlation coefficient of 90%) and had only 1 pulsotype, based on Tenover criteria ([Figure 2](#F2){ref-type="fig"}) ([@R14]). The pulsotype was divided into 7 pulsosubtypes, among which were 1--4 band differences. Five ESC-resistant isolates displayed the same pulsosubtypes (IA or IC) as ESC-susceptible isolates ([Table 1](#T1){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}).

![Dendrogram (left) obtained from cluster analysis of *Xba*I-generated macrorestriction patterns of 38 ciprofloxacin-resistant *Salmonella enterica* serotype Choleraesuis (right). Asterisks indicate extended-spectrum cephalosporin-resistant isolates. A percent scale of similarity is shown above the dendrogram. Pulsed-field gel electrophoresis (PFGE) types are shown between the gel and the dendrogram. H9812, *S. enterica* serotype Braenderup strain H9812, which was used as reference size marker.](04-1153-F2){#F2}

Conclusions
===========

We describe the prevalence of resistance to ciprofloxacin and ESCs among salmonellae isolated from January to May 2004 in Taiwan. We found widespread resistance of *Salmonella* isolates to both ESCs and ciprofloxacin; high prevalence of resistance to ciprofloxacin, ESCs, and both in *S*. Choleraesuis; and widespread prevalence of CMY-2--producing *Salmonella* isolates of various serotypes in Taiwan.

The prevalence of *Salmonella* isolates resistant to both ceftriaxone and ciprofloxacin may pose a therapeutic problem. CMY-2 is one of the AmpC enzymes, which are usually less active against cefepime and cefpirome than ESBLs ([@R15]). Accordingly, we have used cefepime to successfully treat several patients infected with CMY-2--producing and ciprofloxacin-resistant *S*. Choleraesuis ([@R8]). Therefore, AmpC-producing strains should be differentiated from ESBL-producing strains by phenotypic or genotypic methods when ESC-resistant *Salmonella* strains are isolated in the clinical microbiology laboratory ([@R15]).

The ciprofloxacin-resistant rate in *S*. Choleraesuis in Taiwan has been \>60% since 2001; the high prevalence was mainly due to clonal spread of resistant strains ([@R4]--[@R6]). The ciprofloxacin-resistant rate in *S*. Choleraesuis in this report (84.4%) was higher than those reported previously (≤70%) ([@R4]--[@R6]). *bla*~CMY-2~ in *Salmonella* in Taiwan was first reported in 2 *S*. Typhimurium strains isolated in 2000 ([@R3]). The first reported *S*. Choleraesuis strain with *bla*~CMY-2~ was a ciprofloxacin-resistant strain isolated in 2002 ([@R7]). All our 38 ciprofloxacin-resistant *S*. Choleraesuis isolates, including 8 ESC-resistant isolates, were genetically related. Moreover, we found possibly unrelated *bla*~CMY-2~-positive plasmids (lanes 3, 4, 7, 8, 10, and 11 in [Figure 1](#F1){ref-type="fig"}) among closely related isolates ([Figure 2](#F2){ref-type="fig"}). These data together suggest that the development and rapidly increasing prevalence of ESC and ciprofloxacin resistance in *S*. Choleraesuis in Taiwan might result from the extremely high prevalence of ciprofloxacin resistance followed by the horizontal transfer of *bla*~CMY-2~ into ciprofloxacin-resistant epidemic strains rather than from the spread of a clone that had been resistant to ciprofloxacin and ESCs.

All our ciprofloxacin-resistant *Salmonella* isolates tested had mutations in the QRDRs of *gyrA* and *par*, a finding consistent with previously reported results ([@R1],[@R4],[@R5]). The rates of ciprofloxacin resistance in the 3 most common serotypes, Enteritidis, Typhimurium, and Stanley, remained very low (0%--0.6%). Six of 11 ciprofloxacin-resistant isolates in the group of uncommon serotypes belonged to serotype Schwarzengrund and accounted for 42.9% of all serotype Schwarzengrund isolates. Thus, the high rate (5.5%) of ciprofloxacin resistance in this group was in part due to the high prevalence of ciprofloxacin resistance in serotype Schwarzengrund.

*Suggested citation for this article:* Yan J-J, Chiou C-S, Lauderdale T-LY, Tsai S-H, Wu J-J. Cephalosporin and ciprofloxacin resistance in *Salmonella*, Taiwan. Emerg Infect Dis \[serial on the Internet\]. 2005 Jun \[*date cited*\]. <http://dx.doi.org/10.3201/eid1106.041153>

This work was partly supported by a research grant NSC93-2320-B-006-016 from the National Science Council, Taiwan.

Dr. Yan is an associate professor, Department of Pathology, National Cheng Kung University College of Medicine, Tainan, Taiwan. His major research interests are the epidemiology and mechanisms of antimicrobial resistance, especially β-lactamases in gram-negative bacteria.
